Ulrik Spork

Cerebriu’s proven radiology AI solutions detect findings during the initial scan and enable the most appropriate procedures while the patient is still in the scanner. This leads to a simpler, faster MR image acquisition and creates tangible clinical value: Improving technologists’ confidence and freeing up radiologists’ time by ensuring the right data the first time the patient is in the scanner Timely diagnosis of critical findings by prioritizing radiologists’ worklists Improving patient experience and reducing patient recalls

InnoCon Medical is a medical device company developing neuromodulation healthcare solutions for people suffering from incontinence. The company's product UCon is taking advantage of the positive results of Dorsal Genital Nerve stimulation for relieving the symptoms of overactive bladder and fecal incontinence. CAUTION - The device is still limited to investigational use only. --- Privacy statement: By visiting and interacting with this company page, LinkedIn will process your personal data as described in the Joint Controller Addendum (https://legal.linkedin.com/pages-joint-controller-addendum) and in the Privacy Policy (https://www.linkedin.com/legal/privacy-policy). InnoCon Medical uses the data of visitors on this page for marketing purposes. InnoCon Medical jointly controls the personal data together with LinkedIn. InnoCon Medical contact details: Address: Lyngvej 1, 9000 Aalborg CVR: 38635794 Telephone: +45 4051 7712 Email: contact@innoconmedical.dk Website: www.innoconmedical.com Contact person: Jesper Nielsen, CEO

Salient was founded to develop new products based on patented Intellectual property originally developed by scientists at the University of Copenhagen. The technological platform is based on a unique multipurpose gel, which can be adapted depending the development project.

Novo Holdings is a holding and investment company that is responsible for managing the assets and the wealth of the Novo Nordisk Foundation, one of the world’s largest philanthropic enterprise foundations. Novo Holdings is the controlling shareholder of Novo Nordisk A/S and Novonesis A/S and manages an investment portfolio, with a long-term return perspective. In addition to managing a broad portfolio of equities, bonds, real estate, infrastructure and private equity assets, Novo Holdings is a world-leading life sciences investor. Through its Seeds, Venture, Growth, Principal and Planetary Health Investments teams, Novo Holdings invests in life science companies at all stages of development.

Cerebriu’s proven radiology AI solutions detect findings during the initial scan and enable the most appropriate procedures while the patient is still in the scanner. This leads to a simpler, faster MR image acquisition and creates tangible clinical value: Improving technologists’ confidence and freeing up radiologists’ time by ensuring the right data the first time the patient is in the scanner Timely diagnosis of critical findings by prioritizing radiologists’ worklists Improving patient experience and reducing patient recalls

InnoCon Medical is a medical device company developing neuromodulation healthcare solutions for people suffering from incontinence. The company's product UCon is taking advantage of the positive results of Dorsal Genital Nerve stimulation for relieving the symptoms of overactive bladder and fecal incontinence. CAUTION - The device is still limited to investigational use only. --- Privacy statement: By visiting and interacting with this company page, LinkedIn will process your personal data as described in the Joint Controller Addendum (https://legal.linkedin.com/pages-joint-controller-addendum) and in the Privacy Policy (https://www.linkedin.com/legal/privacy-policy). InnoCon Medical uses the data of visitors on this page for marketing purposes. InnoCon Medical jointly controls the personal data together with LinkedIn. InnoCon Medical contact details: Address: Lyngvej 1, 9000 Aalborg CVR: 38635794 Telephone: +45 4051 7712 Email: contact@innoconmedical.dk Website: www.innoconmedical.com Contact person: Jesper Nielsen, CEO

MedTrace is striving to minimize diagnostic uncertainty through better perfusion imaging. Perfusion imaging provides medical professionals with a functional understanding of the organs blood supply inside the patient. MedTrace is developing a solution that will help healthcare providers diagnose patients more accurately and quickly. Our solution allows for absolute blood flow quantification based upon the PET tracer 15O-water, which has long been acknowledged as the gold standard tracer for non-invasive blood flow quantification. Our innovative solution is intended to making 15O-water practically available right next to the PET scanner connected to an onsite cyclotron, with a software package to quantify the myocardial blood flow and perfusion. IMPORTANT NOTICE: MedTrace’s products are not currently cleared for routine use in any markets, including both the US and Europe. In the US, 15O-water is currently under investigation as an investigational drug in a Phase 3 clinical trial. In Europe, its use is in compliance with approvals granted by national drug authorities, in accordance with the specific legislation of each member state.